Bladder Cancer

Bladder Cancer

Immediate adjuvant cisplatin-based combination chemotherapy after radical cystectomy in patients with transitional cell carcinoma of the bladder significantly increased progression-free survival, according to the final results of the EORTC 30994 trial.

A reduced estimated glomerular filtration rate (eGFR) was found to be associated with a significantly increased risk for renal and urothelial cancer, according to the results of a recently published study.

An increased intake of vitamin A may result in a decreased risk for bladder cancer, according to the results of a meta-analysis.

Neoadjuvant treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and should be considered a reasonable option for patients with muscle-invasive urothelial cancer, according to a new study.

Despite symptoms such as hematuria and dysuria, doctors often miss bladder cancer among women or catch it only at an advanced stage.

A noninvasive DNA methylation test using urine samples from patients with non–muscle-invasive bladder cancer can detect cancer recurrence. The test demonstrated both specificity and sensitivity in detecting recurrence.

In an early trial, a patient with bladder cancer has had a 14-month complete response to treatment with the mTOR inhibitor everolimus.


Subscribe to Bladder Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.